Policy & Regulation
Co-authored Paper on Development and Validation of a Sensitive Liquid Chromatography with Time-Of-Flight Mass Spectrometry Assay for In Vivo Pharmacokinetic Study of Epigallocatechin-gallate octaacetate Published in Frontiers in Pharmacology
25 November 2022 - - UK-based clinical stage biopharmaceutical company Aptorum Group Ltd. (NASDAQ: APM) (Euronext Paris: APM) is highlighting the recent publication of a joint effort for the validated analytical method developed for the determination of plasma pro-EGCG and its metabolites after oral administration using ultra performance liquid chromatography coupled to quadrupole time of flight mass spectrometry.

This method was shown to be robust, rapid and sensitive which is a prerequisite for conducting in vivo pharmacokinetic studies.

The paper is titled, "Determination of (-)-epigallocatechin-3-gallate octaacetate and its metabolites in plasma of rats for pharmacokinetic study by ultra-performance-liquid-chromatography coupled to quadrupole-time-of-flight-mass-spectrometry" has been published in Frontiers in Pharmacology which can be downloaded at the following website address: https: //pubmed.ncbi.nlm.nih.gov/36304154/.

Pro-EGCG is a novel small molecule designed for oral administration as a potential non-hormonal based treatment for Endometriosis.

The endometriosis condition is a painful disorder where the endometrial tissue grows outside the uterus, potentially affecting ovaries, fallopian tubes and pelvis tissue, in severe cases affecting fertility.

It has been estimated that endometriosis affects c. 10% of reproductive age women and girls according to the World Health Organisation.

Aptorum Group Ltd. (NASDAQ: APM, Euronext Paris: APM) is a clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications), autoimmune and infectious diseases.

Aptorum has completed two phase I clinical trials for its ALS-4 and orphan drug designated SACT-1 (Neuroblastoma) small molecule drugs and commercializing its NLS-2 NativusWell nutraceutical (menopause).

The pipeline of Aptorum is also enriched through the establishment of drug discovery platforms that enable the discovery of new therapeutics assets through, e.g. systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases; and the co-development and ongoing clinical validation of its novel molecular-based rapid pathogen identification and detection diagnostics technology with Singapore's Agency for Science, Technology and Research.
Login
Username:

Password: